Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Pazopanib
Pazopanib+ interferon alpha 2A · 1 trial · 1 indication
The MTD is defined as the dose at wich two of the patients have experienced dose-limiting toxicity.
Response rate is defined as the percentage of patients with complete response or partial response confirmed according RECIST v.1.1
| Arm | Type | Description |
|---|---|---|
| Pazopanib + interferon | EXPERIMENTAL | Five levels of pazopanib in different doses: 400, 600 and 800 mg / day and interferon alfa 2-A 3, 6 and 9 MIU three times a week, in cycles of 28 days. Treatment will continue until disease progression, unacceptable toxicity, non-compliance or withdrawal of consent by the patient |
| Name | Type | Description |
|---|---|---|
| Pazopanib + interferon alpha 2A | DRUG | Five levels of pazopanib in different doses: 400, 600 and 800 mg / day and interferon alfa 2-A 3, 6 and 9 MIU three times a week, in cycles of 28 days. Treatment will continue until disease progression, unacceptable toxicity, non-compliance or withdrawal of consent by the patient |
Inclusion Criteria: 1. Signed informed consent 2. Age ≥ 18 years. 3. Patients diagnosed histologically clear cell carcinoma of the kidney metastatic or unresectable locally advanced, previously untreated. However, in Phase I may include patients with primary tumors other than renal cell can benefit...
Pazopanib is an investigational small molecule being studied in oncology. Its development covers gastrointestinal stromal tumors, bladder cancer, renal cell carcinoma, soft tissue sarcoma, solid tumors, and glioma. It is currently in Phase 2 clinical development and is not approved by the FDA.
Pazopanib is a kinase inhibitor, belonging to the -nib class of drugs that target kinases. It is being evaluated in multiple cancer types, including renal cell carcinoma and soft tissue sarcoma, where kinase inhibition is a key therapeutic strategy.
Pazopanib is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in various oncology indications.
Pazopanib is in Phase 2 clinical development. It is an investigational drug, meaning it has not received FDA approval and is still being studied in clinical trials. The drug is being evaluated for multiple cancer indications, including gastrointestinal stromal tumors and bladder cancer.
Pazopanib has been studied in several clinical trials. Completed trials include NCT00619424, a Phase 1 study combining pazopanib with erlotinib or pemetrexed in advanced solid tumors; NCT00678977, a Phase 1 study with gemcitabine and cisplatin; NCT00866528, a Phase 1 study with paclitaxel; and NCT00871403, a Phase 2 study with pemetrexed, all in non-small cell lung cancer.
Pazopanib is also known by the brand name Votrient. It is a kinase inhibitor being developed by GSK plc for multiple oncology indications, including renal cell carcinoma and soft tissue sarcoma. The drug is currently in Phase 2 clinical trials and remains investigational.